Author: Jane Meinhardt Source: bizjournals (
click here to go to the source)
Biopsy Sciences LLC received approval to market its new Magne-Cath medical device to the European market, starting this quarter.
The Magne-Cath was developed to use in cardiovascular procedures to retrieve or manipulate objects during stent graft replacement, according to a written statement.
The device makes stent graft procedures faster and improves safety.
Clearwater-based Biopsy Sciences has requested but not yet received U.S. Food and Drug Administration approval to sell Magne-Cath in this country, but received the European approval to market it there, a company spokesman said.
The company plans to start using Magne-Cath in procedures in Rotterdam and Vienna. Biopsy Science also has approval to market in Canada and some South American countries.
Working with Pinellas County Economic Development, Biopsy Sciences used a Florida Target Sector Trade Grant to attend Hospitalar in Brazil, Latin America's largest medical products trade show. The grant program provides event-specific grants on a reimbursable basis to eligible small companies in certain sectors, such as medical device manufacturing.
